KROS
Income statement / Annual
Last year (2024), Keros Therapeutics, Inc.'s total revenue was $3.55 M,
an increase of 2,250.99% from the previous year.
In 2024, Keros Therapeutics, Inc.'s net income was -$187.35 M.
See Keros Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$3.55 M |
$151,000.00 |
$0.00 |
$20.10 M |
$0.00 |
$10.00 M |
$10.00 M |
| Cost of Revenue |
$0.00
|
$815,000.00
|
$1.62 M
|
$898,000.00
|
$605,000.00
|
$17.35 M
|
$10.11 M
|
| Gross Profit |
$3.55 M
|
-$664,000.00
|
-$1.62 M
|
$19.20 M
|
-$605,000.00
|
-$7.35 M
|
-$111,000.00
|
| Gross Profit Ratio |
1
|
-4.4
|
0
|
0.96
|
0
|
-0.73
|
-0.01
|
| Research and Development Expenses |
$173.63 M
|
$135.26 M
|
$87.27 M
|
$55.14 M
|
$33.86 M
|
$17.38 M
|
$10.11 M
|
| General & Administrative Expenses |
$40.75 M
|
$34.83 M
|
$27.53 M
|
$21.33 M
|
$12.80 M
|
$3.18 M
|
$1.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.75 M
|
$34.83 M
|
$27.53 M
|
$21.33 M
|
$12.80 M
|
$3.18 M
|
$1.58 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$7.08 M
|
-$356,000.00
|
-$2.46 M
|
-$558,000.00
|
$237,000.00
|
| Operating Expenses |
$214.38 M
|
$170.09 M
|
$107.71 M
|
$76.47 M
|
$44.20 M
|
$20.01 M
|
$11.32 M
|
| Cost And Expenses |
$214.38 M
|
$170.09 M
|
$107.71 M
|
$76.47 M
|
$44.20 M
|
$20.01 M
|
$11.32 M
|
| Interest Income |
$0.00
|
$0.00
|
$1,000.00
|
$4,000.00
|
$6,000.00
|
$8,000.00
|
$6,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$1,000.00
|
$4,000.00
|
$6,000.00
|
$8,000.00
|
$0.00
|
| Depreciation & Amortization |
$1.23 M
|
$815,000.00
|
$1.62 M
|
$898,000.00
|
$605,000.00
|
$438,000.00
|
$304,000.00
|
| EBITDA |
-$185.82 M |
-$152.18 M |
-$103.06 M |
-$56.37 M |
-$44.92 M |
-$11.89 M |
-$774,000.00 |
| EBITDA Ratio |
-52.34
|
-1007.79
|
0
|
-2.82
|
0
|
-0.98
|
-0.12
|
| Operating Income Ratio |
-59.39
|
-1125.44
|
0
|
-2.8
|
0
|
-1.06
|
-0.17
|
| Total Other Income/Expenses Net |
$23.78 M
|
$16.95 M
|
$10.11 M
|
-$360,000.00
|
$1.12 M
|
-$1.77 M
|
$613,000.00
|
| Income Before Tax |
-$187.05 M
|
-$152.99 M
|
-$104.68 M
|
-$56.73 M
|
-$45.53 M
|
-$12.34 M
|
-$1.08 M
|
| Income Before Tax Ratio |
-52.69
|
-1013.19
|
0
|
-2.82
|
0
|
-1.23
|
-0.11
|
| Income Tax Expense |
$300,000.00
|
$0.00
|
$1,000.00
|
$2.01 M
|
-$172,000.00
|
$8,000.00
|
$257,000.00
|
| Net Income |
-$187.35 M
|
-$152.99 M
|
-$104.68 M
|
-$58.74 M
|
-$45.36 M
|
-$12.34 M
|
-$1.34 M
|
| Net Income Ratio |
-52.78
|
-1013.19
|
0
|
-2.92
|
0
|
-1.23
|
-0.13
|
| EPS |
-5 |
-5.2 |
-4.15 |
-2.52 |
-2.93 |
-1.39 |
-0.15 |
| EPS Diluted |
-5 |
-5.2 |
-4.15 |
-2.52 |
-2.93 |
-1.39 |
-0.15 |
| Weighted Average Shares Out |
$37.44 M
|
$29.45 M
|
$25.24 M
|
$23.33 M
|
$15.51 M
|
$8.88 M
|
$8.88 M
|
| Weighted Average Shares Out Diluted |
$37.44 M
|
$29.45 M
|
$25.24 M
|
$23.33 M
|
$15.51 M
|
$8.88 M
|
$8.88 M
|
| Link |
|
|
|
|
|
|
|
